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Abstracts 
NO-42. PULMONARY METASTASES IN RECURRENT, 
TREATMENT-RESISTANT MENINGIOMA: PROGNOSIS 
AND IDENTIFICATION BY IN-OCTREOTIDE IMAGING 
Daniela Alexandru 1, Michael J. Glantz 2, Lyndon Kim 3, Marc 
C. Chamberlain 4, and Daniela A. Bota 1; 1UC Irvine; 2Pennsylvania State;
3University of Massachusetts; 4University of Washington 
BACKGROUND: Meningioma is the most common extra-axial primary 
intracranial tumor in adults that rarely metastasizes extraneural. Among recog­
nized sites of metastases, lung is the most common, but the importance of lung 
metastases relative to prognosis is unknown. 111 ln-octreotide scintigraphy 
( octreotide scanning) is a valuable imaging modality to evaluate meningiomas 
and response to treatment with somatostatin analogues and has the potential 
to identify extracranial metastatic disease. METHODS: In this retrospective 
multicenter study, adult patients treated for recurrent meningioma who had 
undergone 111ln-octreotide positron-emission tomography/computed tom­
ography (PET /CT) imaging (octreotide scintigraphy) and were found to 
have positive octreotide uptake in their lungs were identified. RES UL TS: Six 
cases were identified with recurrent meningioma (after surgery, radiation 
therapy, and at least one chemotherapy agent) and pulmonary lesions by 
octreotide scintigraphy. Biopsy of a pulmonary lesion in one patient confirmed 
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the diagnosis of metastatic meningioma. Patients with metastatic pulmonary 
involvement identified by 111In-octreotide scintigraphy in this case series 
had an overall survival of 6 months, which is less than that reported 
from previously published series with unknown systemic disease status. 
CONCLUSIONS: 111In-octreotide scintigraphy is useful for assessing both 
central nervous system disease and extraneural metastases. The presence of 
pulmonary metastases appears to negatively predict for survival in patient 
with recurrent meningioma. The utility of 111In-octreotide scintigraphy 
should be considered in staging patients with recurrent meningioma considered 
for further treatment. A prospective study to confirm this finding is warranted. 
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